Barclays’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Barclays’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-500	Closed	-$20K	–	7537
2018 Q4	$20K	Buy	+500	New	+$21.7K	﹤0.01%	5911
2016 Q4	–	Sell	-14,600	Closed	-$877K	–	6972
2016 Q3	$877K	Hold	14,600	–	–	﹤0.01%	2744
2016 Q2	$746K	Buy	+14,600	New	+$624K	﹤0.01%	2868
2015 Q4	–	Sell	-383,800	Closed	-$15.7M	–	6873
2015 Q3	$15.7M	Buy	383,800 +372,200	+3,209%	+$19.4M	0.02%	707
2015 Q2	$696K	Buy	+11,600	New	+$767K	﹤0.01%	3196

Barclays's ONCE Position: Q4 2019 in Review

Barclays sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 95,436 shares — an estimated $9.26M sold.

Barclays first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $14.9M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

Barclays reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Barclays sold 95,436 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $9.26M.
Barclays first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
Barclays's Spark Therapeutics, Inc. Common Stock position peaked at $14.9M in Q2 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.